FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to an antibody that binds with a final product of increased glycation, as well as to a conjugate containing it.
EFFECT: invention is effective for selective targeting protein or peptide with carboxymethyl lysin modification.
14 cl, 1 dwg, 7 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD AND COMPOSITION FOR TREATING CANCER, DESTROYING METASTATIC CANCER CELLS AND PREVENTING METASTASES OF CANCER, USING ANTIBODIES TO END PRODUCTS OF INCREASED GLYCATION (AGE) | 2017 |
|
RU2728964C2 |
| CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY AND USE THEREOF | 2020 |
|
RU2819228C2 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2743464C2 |
| CD40 LIGAND THERAPEUTIC ANTIBODIES | 2018 |
|
RU2770209C2 |
| ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF | 2016 |
|
RU2739208C2 |
| CD47-ANTIGEN-BINDING UNIT AND ITS USE | 2018 |
|
RU2780859C2 |
| HIGH-AFFINITY ANTI-PD-1 AND ANTI-LAG-3 ANTIBODIES AND BISPECIFIC BINDING PROTEINS OBTAINED FROM THEM | 2019 |
|
RU2782381C2 |
| ANTI-PD-L1 ANTIBODY FOR PD-L1 DETECTION | 2018 |
|
RU2758723C2 |
